Business Wire

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...
Monthly Prescribing Reference

Ready-To-Use, Low IgA Gammagard Liquid ERC Approved for Primary Immunodeficiency

Commercialization of Gammagard Liquid ERC is expected to begin in 2026. The Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion [human] 10% solution) as a ...
Monthly Prescribing Reference

Gammagard Liquid ERC Now Available for Primary Immunodeficiency

Credit: Takeda. Gammagard Liquid ERC is supplied as a 10% IgG (100mg/mL) solution of less than or equal to 2µg/mL of IgA. Gammagard Liquid ERC is a ready-to-use, low IgA immunoglobulin therapy that ...
Healthline

Is Weight Gain a Side Effect of IVIG?

Some IVIG brands, like Gammagard, contain added sugar. This could cause your blood glucose to rise temporarily. But studies don’t show weight gain as a typical side effect of IVIG. Intravenous ...
Business Wire

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

− GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Now Available by Prescription for Intravenous or Subcutaneous Use in People Aged ...